Pacira BioSciences, Inc.
- Open
- 26.01
- Day high
- 26.39
- Day low
- 25.88
- Prev close
- 25.90
- Volume
- 27K
- Mkt cap
- $1.0B
- P/E (TTM)
- 74.2
- EPS (TTM)
- $0.35
- P/B
- 1.6
- P/S
- 1.4
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$443K over the last 3 months (0 open-market buys, 3 sales)
- 🏛Institutions mixed (13F)
Pacira BioSciences, Inc. (PCRX) is a Healthcare company listed on NASDAQ. The stock is down 6% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 3 sales (SEC Form 4).
Pacira BioSciences, Inc. (PCRX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 3 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
PCRX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 4, 2026 | $0.65 | $0.73 | +13.0% | $192M | +0.7% |
| Apr 30, 2026 | $0.61 | $0.60 | -1.6% | $177M | +3.2% |
| Nov 6, 2025 | $0.65 | $0.70 | +7.7% | $180M | -11.1% |
| May 8, 2025 | $0.57 | $0.62 | +8.8% | $169M | -9.9% |
| Feb 27, 2025 | $0.78 | $0.91 | +16.7% | $187M | +1.0% |
| Jul 30, 2024 | $0.73 | $0.89 | +21.9% | $178M | +3.2% |
| Feb 29, 2024 | $0.89 | $0.89 | +0.1% | $181M | -0.0% |
| Nov 2, 2023 | $0.84 | $0.72 | -13.9% | $164M | -8.9% |
| Aug 2, 2023 | $0.80 | $0.78 | -2.7% | $169M | -3.5% |
| May 3, 2023 | $0.60 | $0.53 | -11.5% | $160M | -0.2% |
| Feb 28, 2023 | $0.80 | $0.80 | -0.4% | $172M | -0.9% |
| Nov 3, 2022 | $0.73 | $0.64 | -12.3% | $167M | -0.2% |
PCRX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | SLONIN JONATHANofficer: Chief Medical Officer | Sell | 3,040 | $23.23 |
| Jun 12, 2026 | CHRISTIE CHRISTOPHERdirector | Grant | 10,891 | $23.42 |
| Jun 12, 2026 | Young Alethiadirector | Grant | 10,891 | $23.42 |
| Jun 12, 2026 | Froimson Markdirector | Grant | 10,891 | $23.42 |
| Jun 12, 2026 | Brege Lauradirector | Grant | 6,405 | — |
| Jun 12, 2026 | Froimson Markdirector | Grant | 6,405 | — |
| Jun 12, 2026 | WIGGANS THOMAS Gdirector | Grant | 32,675 | $23.42 |
| Jun 12, 2026 | Young Alethiadirector | Grant | 6,405 | — |
| Jun 12, 2026 | Hirawat Samitdirector | Grant | 6,405 | — |
| Jun 12, 2026 | CHRISTIE CHRISTOPHERdirector | Grant | 6,405 | — |
| Jun 12, 2026 | YANG MICHAEL J.director | Grant | 10,891 | $23.42 |
| Jun 12, 2026 | Brege Lauradirector | Grant | 10,891 | $23.42 |
| Jun 12, 2026 | YANG MICHAEL J.director | Grant | 6,405 | — |
| Jun 12, 2026 | RIKER LAURENofficer: Senior Vice President, Finance | Sell | 6,115 | $23.50 |
| Jun 12, 2026 | Hirawat Samitdirector | Grant | 10,891 | $23.42 |
Source: PCRX SEC Form 4 filings, latest Aug 18, 2026. For informational purposes only — not investment advice.
See the full PCRX insider & 13F page →Pacira BioSciences, Inc. company profile
Overview
Pacira BioSciences, Inc. (NASDAQ:PCRX) is a Tampa, Florida-based specialty pharmaceutical company founded in 2006 that focuses on developing and commercializing non-opioid pain management and regenerative health solutions. Originally incorporated as Pacira Pharmaceuticals, the company rebranded to Pacira BioSciences in April 2019 to reflect its expanded focus beyond traditional pharmaceuticals into innovative biotechnology solutions. The company went public in February 2011 and has established itself as a leader in the non-opioid pain management space, addressing the critical need for alternatives to opioid-based treatments in surgical and chronic pain settings.
Business
Pacira BioSciences operates in the specialty pharmaceutical industry, specifically focusing on non-opioid pain management and regenerative health solutions. The company's business centers around three primary commercial products that address different aspects of pain management without relying on opioid medications, which have been associated with addiction risks and adverse side effects. The company's flagship product is EXPAREL (bupivacaine liposome injectable suspension), which represents approximately 75-80% of total revenues. EXPAREL is a long-acting local anesthetic that provides pain relief for up to 72 hours following surgery. The product uses Pacira's proprietary multivesicular liposome technology, which encapsulates the anesthetic drug bupivacaine in microscopic spheres that slowly release the medication over time. This extended-release mechanism allows patients to experience prolonged pain relief from a single injection during surgery, reducing the need for post-operative opioid medications. EXPAREL is primarily used in soft tissue infiltration during surgical procedures and nerve blocks. The second major product is ZILRETTA (triamcinolone acetonide extended-release injectable suspension), accounting for approximately 15-20% of revenues. ZILRETTA is an extended-release corticosteroid injection designed to treat osteoarthritis pain in the knee. Using the same multivesicular liposome technology as EXPAREL, ZILRETTA provides sustained anti-inflammatory effects for up to three months from a single intra-articular injection, offering an alternative to frequent steroid injections or oral pain medications. The third commercial product is the iovera system, representing roughly 3-5% of revenues. This is a handheld cryoanalgesia device that uses controlled cold temperatures to temporarily interrupt nerve signal transmission, providing non-pharmacological pain relief. The system is used for various chronic pain conditions and offers a drug-free treatment option that can provide pain relief for several months. Beyond these commercial products, Pacira is developing an innovative pipeline including PCRX-201, a gene therapy approach for osteoarthritis that represents a potential breakthrough in treating joint pain by addressing the underlying disease process rather than just managing symptoms.
Revenue model
Pacira BioSciences generates revenue primarily through direct product sales to healthcare providers, including hospitals, ambulatory surgical centers, and physician offices. The company operates with a traditional pharmaceutical business model where it manufactures and sells its proprietary products directly to healthcare institutions and practitioners who then administer them to patients. The company's customers are healthcare providers rather than individual patients, making this a business-to-business (B2B) model. Hospitals represent the largest customer segment for EXPAREL, particularly for inpatient surgical procedures, while ambulatory surgical centers and physician offices are important channels for outpatient procedures. For ZILRETTA, the primary customers are orthopedic specialists and rheumatologists who treat osteoarthritis patients. The iovera system is sold to pain management specialists and other physicians treating chronic pain conditions. Revenue growth and profitability are influenced by several key factors. Reimbursement policy represents the most significant driver, as healthcare providers' adoption depends heavily on adequate insurance coverage. The recent passage of the NOPAIN Act, which provides separate Medicare reimbursement for non-opioid pain management products starting in 2025, is expected to significantly improve adoption by ensuring providers receive appropriate compensation for using these more expensive alternatives to generic opioids. Clinical evidence and outcomes data also drive adoption, as healthcare providers increasingly focus on value-based care and patient outcomes. Products that demonstrate superior pain control, reduced opioid consumption, and shorter hospital stays can command premium pricing and broader adoption. Competitive pressures represent a key margin risk, particularly the potential entry of generic competitors for EXPAREL, which could erode both pricing and market share. Manufacturing efficiency and scale economics affect gross margins, with the company investing in larger, more efficient production facilities to reduce per-unit costs. Regulatory factors, including FDA approvals for label expansions and new indications, can create new revenue opportunities and support premium pricing. The company's gross margins have improved from the mid-70% range to approaching 80%, driven by manufacturing efficiencies and product mix optimization. Operating leverage allows the company to expand margins as revenues grow, since much of the sales and marketing infrastructure can support higher volumes without proportional cost increases.
Competitive moat
Pacira BioSciences possesses a moderate but potentially vulnerable moat built primarily on proprietary technology, regulatory barriers, and established market relationships. The company's core competitive advantage lies in its multivesicular liposome drug delivery platform, which enables extended-release formulations that are difficult to replicate. This technology creates a formulation patent barrier that has protected EXPAREL from generic competition, though this protection faces ongoing legal challenges. The company's intellectual property portfolio includes multiple patents covering both the drug delivery technology and specific product formulations, with EXPAREL patent protection recently extended to 2039 through litigation settlements. However, patent litigation remains an ongoing risk, with generic manufacturers challenging these patents in court. The complexity of the multivesicular liposome manufacturing process creates additional barriers to entry, as competitors must not only navigate patent challenges but also develop sophisticated manufacturing capabilities. Regulatory barriers provide another layer of protection, as competitors must conduct expensive clinical trials to demonstrate bioequivalence and safety for FDA approval. The specialized nature of these products requires significant clinical development investment, which deters some potential competitors. Market position and relationships with healthcare providers create switching costs and brand loyalty, particularly for EXPAREL, which has become the standard of care in many surgical settings. The company's established sales force and clinical support infrastructure represent valuable assets that would be expensive for competitors to replicate. However, the moat faces significant threats. Generic competition remains the primary risk, with multiple companies pursuing abbreviated new drug applications (ANDAs) for EXPAREL. If generic competitors successfully challenge patents or develop alternative formulations, they could capture significant market share through lower pricing. The company's dependence on a single major product (EXPAREL) makes it particularly vulnerable to this threat. Technological disruption could also erode the moat, as alternative pain management approaches, including new drug delivery systems, non-pharmacological treatments, or entirely different therapeutic modalities, could reduce demand for current products. The competitive landscape in pain management continues to evolve rapidly, with both pharmaceutical and medical device companies developing innovative alternatives.
Risks & safety
Pacira BioSciences demonstrates a solid financial position with adequate liquidity and manageable debt levels, though valuation metrics suggest limited margin of safety at current prices. **Liquidity and Solvency:** 1. Strong cash position of $284 million as of Q1 2025, providing substantial operating runway 2. Current ratio of 2.41 indicates healthy short-term liquidity 3. Positive free cash flow generation of $27 million in Q1 2025 and $179 million for full year 2024 4. Debt-to-equity ratio of 0.80 represents moderate leverage but manageable debt burden 5. No immediate solvency concerns given strong cash generation and balance sheet position **Valuation Metrics:** 1. Price-to-earnings ratio of 59.7x appears elevated for a mature pharmaceutical company 2. EV/EBITDA of 11.2x suggests moderate valuation relative to cash flow generation 3. Price-to-book ratio of 1.44x indicates modest premium to book value 4. Graham number analysis suggests potential overvaluation relative to conservative value metrics **Other Considerations:** 1. Patent litigation risk creates uncertainty around future cash flows and competitive position 2. Concentration risk from EXPAREL dependence (75-80% of revenues) limits diversification 3. Regulatory and reimbursement dependency adds external risk factors beyond company control
Recent development
Over the past few years, Pacira BioSciences has undergone significant strategic transformation, moving from a single-product company to a diversified non-opioid pain management platform. The company launched its "5x30" strategic plan aimed at achieving ambitious growth targets by 2030, including serving over 3 million patients annually and expanding gross margins by 5 percentage points. A major strategic milestone was securing the passage and implementation of the NOPAIN Act, which provides separate Medicare reimbursement for non-opioid pain management products beginning in 2025. This regulatory achievement addresses the primary barrier to adoption - inadequate reimbursement - and is expected to significantly expand market access for EXPAREL and iovera. The company has made substantial investments in its pipeline and technology platform. The acquisition of GQ Bio brought a novel gene therapy delivery platform, leading to the development of PCRX-201, a potential disease-modifying treatment for osteoarthritis. Early clinical results show promising one to two-year pain relief, representing a potential breakthrough beyond current symptomatic treatments. Manufacturing and operational improvements have been a key focus, with the company investing in larger, more efficient production facilities including a new 200-liter manufacturing facility in San Diego. These investments have driven gross margin expansion from the mid-70% range toward 80%. The company has also strengthened its market access and commercial capabilities, establishing partnerships with major Group Purchasing Organizations (GPOs) covering approximately 50% of the addressable market. These partnerships improve pricing stability and market penetration. Product line extensions have expanded addressable markets, including new indications for EXPAREL in lower extremity nerve blocks and ongoing development of ZILRETTA for shoulder osteoarthritis. The iovera system received new CMS reimbursement codes and launched innovative SmartTip technology for expanded applications. Recent capital allocation initiatives include a $300 million stock repurchase program and the settlement of major patent litigation, extending EXPAREL exclusivity to 2039 while providing greater competitive certainty.
PCRX company profile · for informational purposes only — not investment advice.
Track PCRX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free